seralutinib
Generic: GB002·Code: GB002
seralutinib: developed by 2 companies · 1 FDA decision. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Gossamer Bio, Inc. (GOSS) | Phase 3 |
| XOMA Royalty Corporation (XOMA) | Phase 3 |
FDA Decisions
FDA_MeetingCompany expects to meet with the U.S. FDA to discuss the path forward for seralutinib in pulmonary arterial hypertension.(GOSS)
Frequently asked questions
Who is developing seralutinib?
seralutinib is being developed by Gossamer Bio, Inc., XOMA Royalty Corporation.
What is seralutinib's latest FDA decision?
The most recent tracked FDA decision for seralutinib is FDA_Meeting for Company expects to meet with the U.S. FDA to discuss the path forward for seralutinib in pulmonary arterial hypertension..
Get deeper analysis on seralutinib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis